EA200971020A1 - TREATMENT OF CARDIOVASCULAR DISEASE AND DYSLIPIDEMIA WITH THE USE OF SECRETARY PHOSPHOLIPASE A SPLA INHIBITORS AND SPLA INHIBITOR TREATMENT METHODS - Google Patents
TREATMENT OF CARDIOVASCULAR DISEASE AND DYSLIPIDEMIA WITH THE USE OF SECRETARY PHOSPHOLIPASE A SPLA INHIBITORS AND SPLA INHIBITOR TREATMENT METHODSInfo
- Publication number
- EA200971020A1 EA200971020A1 EA200971020A EA200971020A EA200971020A1 EA 200971020 A1 EA200971020 A1 EA 200971020A1 EA 200971020 A EA200971020 A EA 200971020A EA 200971020 A EA200971020 A EA 200971020A EA 200971020 A1 EA200971020 A1 EA 200971020A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- spla
- inhibitors
- cvd
- treatment
- dyslipidemia
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Введение ингибиторов sPLA, как было обнаружено, снижает уровни холестерина, образование атеросклеротической бляшки аневризмы аорты у мышей и снижает уровни холестерина и триглицеридов у людей. Примечательно, что введение ингибиторов sPLA, как обнаружили, снижало уровни холестерина, даже когда ингибитор вводили один раз в день. Следовательно, в настоящем документе предлагаются способы лечения дислипидемии, CVD и состояний, ассоциированных с CVD, таких как атеросклероз и метаболический синдром, посредством введения одного или нескольких ингибиторов sPLA. В значительной степени введение ингибиторов sPLAи различных соединений, применяемых при лечении CVD, таких как, например, статины, приводило к большему снижению уровней LDL и частиц LDL синергичным образом. Кроме того, введение ингибиторов sPLAи статинов приводило к синергичному уменьшению площади бляшки. Следовательно, в настоящем документе также предлагаются композиции, содержащие один или несколько ингибиторов sPLAи одно или несколько соединений, применяемых при лечении CVD, таких как, например, статины, и способы применения таких композиций для лечения дислипидемии, CVD и состояний, ассоциированных с CVD, таких как атеросклероз и метаболический синдром.The administration of sPLA inhibitors has been found to reduce cholesterol levels, the formation of atherosclerotic plaque in aortic aneurysms in mice, and lower cholesterol and triglycerides in humans. Notably, the administration of sPLA inhibitors was found to lower cholesterol levels even when the inhibitor was administered once a day. Therefore, the present document provides methods for treating dyslipidemia, CVD, and CVD associated conditions, such as atherosclerosis and metabolic syndrome, by administering one or more sPLA inhibitors. To a large extent, the introduction of sPLA inhibitors and various compounds used in the treatment of CVD, such as, for example, statins, led to a greater decrease in the levels of LDL and LDL particles in a synergistic manner. In addition, the administration of sPLA and statin inhibitors resulted in a synergistic reduction in plaque area. Therefore, this document also provides compositions containing one or more sPLA inhibitors and one or more compounds useful in the treatment of CVD, such as, for example, statins, and methods of using such compositions for the treatment of dyslipidemia, CVD and CVD associated conditions, such like atherosclerosis and metabolic syndrome.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91591007P | 2007-05-03 | 2007-05-03 | |
| US96959107P | 2007-08-31 | 2007-08-31 | |
| US87486907A | 2007-10-18 | 2007-10-18 | |
| PCT/US2008/062577 WO2008137803A1 (en) | 2007-05-03 | 2008-05-02 | Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase a2 (spla2) inhibitors and spla2 inhibitor combination therapies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA200971020A1 true EA200971020A1 (en) | 2010-10-29 |
Family
ID=39943969
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA200971020A EA200971020A1 (en) | 2007-05-03 | 2008-05-02 | TREATMENT OF CARDIOVASCULAR DISEASE AND DYSLIPIDEMIA WITH THE USE OF SECRETARY PHOSPHOLIPASE A SPLA INHIBITORS AND SPLA INHIBITOR TREATMENT METHODS |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP2154958A4 (en) |
| JP (1) | JP2010526152A (en) |
| CN (1) | CN101742907A (en) |
| AU (1) | AU2008247451A1 (en) |
| BR (1) | BRPI0811486A2 (en) |
| CA (1) | CA2686157A1 (en) |
| EA (1) | EA200971020A1 (en) |
| WO (1) | WO2008137803A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI1007032A2 (en) * | 2009-01-08 | 2015-08-18 | Anthera Pharmaceuticals Inc | A2 secretpha phosphatasease inhibitor (spla) and niacin drug compositions and method for treating cardiovascular disease and dyslipidemia |
| RU2483707C1 (en) * | 2012-05-04 | 2013-06-10 | Лира Талгатовна Гильмутдинова | Method of sanatorium therapy of patients with metabolic syndrome and arterial hypertension with application of sulfide baths |
| CN115040508A (en) * | 2022-07-28 | 2022-09-13 | 上海市同仁医院 | Application of indole-3-acetaldehyde in preparing novel anti-obesity active preparation |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GT199800127A (en) * | 1997-08-29 | 2000-02-01 | THERAPEUTIC COMBINATIONS. | |
| EA003277B1 (en) * | 1998-05-01 | 2003-04-24 | Эли Лилли Энд Компани | sPLA2 INHIBITOR ESTER |
| AU2001236440A1 (en) * | 2000-01-25 | 2001-08-07 | Eli Lilly And Company | Method for the treatment of inflammation with spla2 inhibitors |
| WO2002008189A1 (en) * | 2000-07-24 | 2002-01-31 | The University Of Queensland | Compounds and inhibitors of phospholipases |
| TWI314457B (en) * | 2001-03-19 | 2009-09-11 | Shionogi & Co | |
| US20060094693A1 (en) * | 2004-09-21 | 2006-05-04 | Point Therapeutics, Inc. | Methods and compositions for treating glucose-associated conditions, metabolic syndrome, dyslipidemias and other conditions |
| US7666898B2 (en) * | 2005-11-03 | 2010-02-23 | Ilypsa, Inc. | Multivalent indole compounds and use thereof as phospholipase-A2 inhibitors |
-
2008
- 2008-05-02 EP EP08747605A patent/EP2154958A4/en not_active Withdrawn
- 2008-05-02 BR BRPI0811486-2A2A patent/BRPI0811486A2/en not_active IP Right Cessation
- 2008-05-02 WO PCT/US2008/062577 patent/WO2008137803A1/en active Application Filing
- 2008-05-02 AU AU2008247451A patent/AU2008247451A1/en not_active Abandoned
- 2008-05-02 JP JP2010507578A patent/JP2010526152A/en active Pending
- 2008-05-02 CN CN200880023061A patent/CN101742907A/en active Pending
- 2008-05-02 EA EA200971020A patent/EA200971020A1/en unknown
- 2008-05-02 CA CA002686157A patent/CA2686157A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2154958A1 (en) | 2010-02-24 |
| WO2008137803A1 (en) | 2008-11-13 |
| CA2686157A1 (en) | 2008-11-13 |
| EP2154958A4 (en) | 2011-05-04 |
| CN101742907A (en) | 2010-06-16 |
| JP2010526152A (en) | 2010-07-29 |
| AU2008247451A1 (en) | 2008-11-13 |
| BRPI0811486A2 (en) | 2014-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA200602273A1 (en) | Substituted Heteroaryl and Phenylsulfamic Compounds | |
| EA200701229A1 (en) | OMEGA-3 FATTY ACIDS AND DISLIPIDEMIC AGENT FOR LIPID THERAPY | |
| NZ743714A (en) | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy | |
| EA200800356A1 (en) | TREATING CHOLESTEROL ABSORPTION WITH AZETIDINONE AND OMEGA-3 INHIBITOR WITH FATTY ACIDS AND THEIR COMBINED DRUG | |
| BR0315381A (en) | A compound or a pharmaceutically acceptable salt thereof, a pharmaceutical composition, and methods for inhibiting the activity of the dipeptidyl peptidase-iv enzyme in a mammal in need thereof, to treat diabetes in a mammal in need thereof, to treat non-insulin dependent diabetes (type 2). 2) in a mammal in need of it, to treat hyperglycemia in a mammal in need of it, to treat obesity in a mammal in need of it, to treat one or more lipid disorders selected from the group of dyslipidemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolaemia, low hdl and high ldl in a mammal in need of it, and to treat in a mammal in need of one or more conditions | |
| EA200901032A1 (en) | COMPOUNDS AND COMPOSITIONS AS GPR119 ACTIVITY MODULATORS | |
| CL2012001124A1 (en) | Pharmaceutical composition comprising a concentrated therapeutic extract, comprising phospholipids in a concentration of 60 to 99% and used to treat cardiovascular diseases, reduce triglyceride levels, reduce LDL cholesterol and increase HDL cholesterol. | |
| MX2009003727A (en) | Boronic acids and esters as inhibitors of fatty amide hydrolase. | |
| EA200870415A1 (en) | QUINAZOLINS TO INHIBIT PDK 1 | |
| HK1136283A1 (en) | Compounds for the prevention and treatment of cardiovascular diseases | |
| DK2358717T3 (en) | AMINOTETRAHYDROPYRANES AS DIPEPTIDYLPEPTIDASE-IV INHIBITORS TREATMENT OR PREVENTION OF DIABETES | |
| EA200901166A1 (en) | CONNECTIONS AND COMPOSITIONS AS GPR 119 ACTIVITY MODULATORS | |
| TWI367886B (en) | Proteasome inhibitors and methods of using the same | |
| EA201300471A1 (en) | SUBSTITUTED 6-AMINONICOTINAMIDES AS KCNQ2 / 3 MODULATORS | |
| BR112015005117A2 (en) | methods of treating alzheimer's disease and its pharmaceutical compositions | |
| MA32393B1 (en) | Compounds and compounds that act as kinase inhibitors | |
| EA200500629A1 (en) | ACTIVATORS OF RECEPTORS ACTIVATED BY PROLIFERATOR PEROXIS (PPAR) | |
| EA200970088A1 (en) | METABOLISM MODULATORS AND TREATMENT OF RELATED DISABILITIES | |
| CY1109551T1 (en) | PROTECTIVE SUSPENSIONS AND METHODS OF USING THESE | |
| WO2010079431A3 (en) | Compounds for the prevention and treatment of cardiovascular disease | |
| MX2013006598A (en) | Faah inhibitors. | |
| EA200601442A1 (en) | SUBSTITUTED HETEROARIL- AND PHENYLSULFAMOIL DERIVATIVES | |
| BR112014014410A2 (en) | compositions and methods comprising a lipolytic enzyme variant | |
| MA37886B1 (en) | New bicyclic pyridinones | |
| EA201200570A1 (en) | COMPOUNDS AND COMPOSITIONS AS GPR119 ACTIVITY MODULATORS |